Obesity Intervention: A New Era Of Discovery And Innovation
Driven by a vast and underserved market in dire need of safer, less-invasive, more effective solutions, manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease. Indeed the obesity intervention paradigm is rapidly changing as ongoing research provides new insights into the underlying mechanisms behind obesity and bariatric surgery, heralding a new era where the primary treatment target for bariatric surgery is becoming disease specific, rather than targeted at obesity alone.
You may also be interested in...
At the end of October, Apollo Endosurgery announced that it would acquire certain obesity assets from Allergan: Lap-Band, one of the most well-known brands in bariatric surgery, and Orbera, Allergan’s intra-gastric balloon system, the leading such product in Europe. It’s not unusual these days for large companies to unload under-performing businesses, but the Allergan deal is striking because of its choice of partner – Apollo Endosurgery is a small organization acquiring a much larger one.
USGI Medical received a conditional investigational device exemption from FDA to test its catheter for treating obesity using an incisionless, endoscopic procedure.
Belgium-based Endo Tools Therapeutics SA is developing devices that will enable NOTES procedures to treat disorders such as type 2 diabetes, morbid obesity, and digestive tract tumors. Its Endomina device is a universal, multi-channel triangulation platform for use on any existing endoscope through the natural orifices, such as the esophagus.